Poster lunch (ID 46) Poster display session

97P - Adjuvant trastuzumab in stage I breast cancer with the tumour size < 1 cm: Our centre experience (ID 493)

Presentation Number
97P
Lecture Time
12:15 - 12:15
Speakers
  • Helena Belikova (Glasgow, United Kingdom)
Session Name
Poster lunch (ID 46)
Location
Exhibition area, MARITIM Hotel Berlin, Berlin, Germany
Date
03.05.2019
Time
12:15 - 13:00

Abstract

Background

Small node-negative breast cancers measuring less than 1 cm are generally associated with a favorable prognosis. Around 10% of these malignances exhibit human epidermal growth factor receptor 2 (HER2) overexpression and/or amplification. Patients with HER2+ tumors have a higher risk of recurrence. Several large retrospective reviews have reported a lower overall survival among HER2+ cases in the pT1a/b N0 patient group where adjuvant treatment was not given. In this retrospective study we looked at our institutional experience of using trastuzumab (Herceptin®) in early breast cancer, and how the outcomes compared to the same stage of HER2+ group not treated with Herceptin®, or HER2- group.

Methods

A retrospective review of 963 early breast cancer cases staged pT1a and pT1b N0 who underwent surgical treatment in 2009-2015.The data was collected using clinical electronic resources including Clinical Portal, TrakCare, ChemoCare and PACS. Statistical analysis comparing HER2+ and HER2- groups using an individualised pairwise matching was performed.

Results

In total, 1045 cases of breast cancer treated in the Beatson Cancer Centre between 2009 and 2015 were analyzed. 82 patients were excluded from the analysis due to an upstaging. We had 4.4% of pT1/pT2 N0 breast cancers which were HER2 + (42 cases). We have matched HER2+ group with 42 cases from the HER2- group using age, tumor size, grade, hormonal status, adjuvant treatment and type of surgery, to allow a direct comparison. The recurrence rate was 2.3% in HER2- group compared to 6.8% in HER2+ group when Herceptin® was not given. From our small sample size of 42 HER2+ cases, 31% have received adjuvant Herceptin® and none of those patients had a recurrent disease with an average follow up of 5 years.

Conclusions

The risk of recurrent breast cancer after completion of standard radical treatment appears to be higher in HER2+ve cases even in early stage disease with tumor size less than 1 cm. In HER2+ve breast cancer staged pT1a/pT1b N0, adjuvant treatment with Herceptin® may reduce the risk of recurrence. The sample size is too small to draw any statistically significant conclusions but our data come in tune with the findings from the other trials.

Legal entity responsible for the study

Abdulla Alhasso.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

Collapse